Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zur Wirksamkeit und Sicherheit von Dabrafenib plus Trametinib bei vorbehandelten Patienten mit lokal fortgeschrittenem oder metastasiertem, radioaktivem Jod-refraktärem BRAFV600E-Mutations-positivem differenziertem Schilddrüsenkrebs

17. September 2026 aktualisiert von: Novartis Pharmaceuticals

Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit von Dabrafenib plus Trametinib bei vorbehandelten Patienten mit lokal fortgeschrittenem oder metastasiertem, radioaktivem Jod-refraktärem BRAFV600E-Mutations-positivem differenziertem Schilddrüsenkrebs (DTC)

The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a global, multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that is positive for the BRAF V600E mutation, refractory to radioactive iodine (RAI), and has progressed following prior vascular endothelial growth factor receptor (VEGFR) targeted therapy.

After eligibility assessment, patients will be randomized in a 2:1 ratio to receive either dabrafenib plus trametinib or placebo. Patients will be stratified by the number of prior VEGFR targeted therapies (one versus two) and prior lenvatinib treatment (yes versus no).

The scientific objective guiding the primary estimand is based on progression-free survival (PFS) as per blinded independent review committee (BIRC) assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

This study will enroll approximately 150 patients.

Patients randomized to the placebo arm who experience disease progression as per RECIST 1.1 confirmed by BIRC and meet eligibility criteria will have the option to cross over to the open-label combination of dabrafenib plus trametinib.

Treatment may continue beyond RECIST 1.1 disease progression (confirmed by BIRC) if, in the investigator's judgment, there is evidence of clinical benefit and the patient wishes to remain on study treatment. In cases where there is a discrepancy between local site determination and BIRC (for example, disease progression determined locally but not by BIRC), the patient should not be discontinued from study treatment until progression is confirmed by BIRC or, at a minimum, until one additional tumor assessment has been completed, provided this is clinically acceptable.

After treatment discontinuation, all patients will be followed for safety and efficacy evaluations during the post-treatment follow-up period. Subsequently, patient status will be collected every 12 weeks as part of survival follow-up.

This study is ongoing, and enrollment was completed on 09-May-2024. The primary analysis was performed after all patients had either completed at least 16 weeks of treatment or discontinued early, and after approximately 95 PFS events had occurred.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

153

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Buenos Aires
      • CABA, Buenos Aires, Argentinien, C1417DTB
        • Novartis Investigative Site
    • Rio de Janeiro
      • Rio de Janiero, Rio de Janeiro, Brasilien, 20231-050
        • Novartis Investigative Site
    • Santa Catarina
      • Blumenau, Santa Catarina, Brasilien, 89015-200
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 01246-000
        • Novartis Investigative Site
      • Beijing, China, 100730
        • Novartis Investigative Site
      • Beijing, China, 100036
        • Novartis Investigative Site
      • Guangzhou, China, 510060
        • Novartis Investigative Site
      • Shanghai, China, 200233
        • Novartis Investigative Site
      • Tianjin, China, 300052
        • Novartis Investigative Site
      • Tianjin, China, 300480
        • Novartis Investigative Site
    • Fujian
      • Fuzhou, Fujian, China, 350014
        • Novartis Investigative Site
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Novartis Investigative Site
    • Hunan
      • Changsha, Hunan, China, 410013
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210006
        • Novartis Investigative Site
      • Nanjing, Jiangsu, China, 210009
        • Novartis Investigative Site
      • Xuzhou, Jiangsu, China, 221003
        • Novartis Investigative Site
    • Jilin
      • Changchun, Jilin, China, 130033
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Novartis Investigative Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300121
        • Novartis Investigative Site
      • Chennai, Indien, 600020
        • Novartis Investigative Site
    • Haryana
      • Hisar, Haryana, Indien, 125005
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110029
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • Novartis Investigative Site
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia, 59100
        • Novartis Investigative Site
    • Pulau Pinang
      • George Town, Pulau Pinang, Malaysia, 10450
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malaysia, 93586
        • Novartis Investigative Site
      • Seoul, Südkorea, 03080
        • Novartis Investigative Site
      • Seoul, Südkorea, 05505
        • Novartis Investigative Site
      • Seoul, Südkorea, 06351
        • Novartis Investigative Site
      • Seoul, Südkorea, 06591
        • Novartis Investigative Site
      • Tainan, Taiwan, 704302
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Türkei (türkiye), 34098
        • Novartis Investigative Site
    • Merkez
      • Edirne, Merkez, Türkei (türkiye), 22030
        • Novartis Investigative Site
    • Yenimahalle
      • Ankara, Yenimahalle, Türkei (türkiye), 06500
        • Novartis Investigative Site
    • Yuregir
      • Adana, Yuregir, Türkei (türkiye), 01250
        • Novartis Investigative Site
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Northwestern University Med School
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital
      • Hanoi, Vietnam, 100000
        • Novartis Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 99 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Key Inclusion Criteria:

  • Signed informed consent
  • Male or female ≥ 18 years of age at time of informed consent
  • Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid carcinoma
  • Radioactive-iodine refractory disease
  • BRAF V600E mutation-positive tumor sample as per central laboratory result
  • Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapies
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • At least one measurable lesion as defined by RECIST v1.1.

Key Exclusion Criteria:

  • Anaplastic or medullary carcinoma of the thyroid
  • Previous treatment with a BRAF inhibitor and/or a MEK inhibitor
  • Concomitant RET Fusion-Positive Thyroid Cancer
  • Treatment with any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization
  • Treatment with any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
  • Treatment with radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization
  • A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy

Other inclusion/exclusion criteria may apply.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Dabrafenib plus Trametinib

Eligible participants will receive Dabrafenib 150 mg twice a day (BID) and Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor.

Dabrafenib 150 mg capsule administered orally twice a day (BID)

Andere Namen:
  • DRB436

Trametinib 2 mg tablet administered once a day (QD)

Andere Namen:
  • TMT212
Placebo-Komparator: Dabrafenib Placebo plus Trametinib Placebo

Eligible participants will receive matching placebo for Dabrafenib 150 mg twice a day (BID) and matching placebo for Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor.

matching placebo tablet for Trametinib 2 mg will be administered orally once a day (QD)

matching placebo capsule for Dabrafenib 150 mg will be administered orally twice a day (BID)

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression Free Survival (PFS)
Zeitfenster: From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years

Progression Free Survival (PFS) was defined as the time from the date of randomization to the date of the first documented progression according to RECIST 1.1 based on Blinded Independent Review Committee (BIRC) assessment, or death due to any cause.

The primary analysis was conducted after all patients had either completed a minimum of 16 weeks of treatment or discontinued earlier, and following the occurrence of approximately 95 PFS events (Data cut-off date for the primary analysis was 22 January 2025).

From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Response Rate (ORR)
Zeitfenster: From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)

Overall Response Rate (ORR) was defined as the proportion of participants who had a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1.

From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)
Overall Survival (OS)
Zeitfenster: From randomization to death assessed up to approximately 5 years

Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause.

From randomization to death assessed up to approximately 5 years
Duration of Response (DOR)
Zeitfenster: From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)

Duration of Response (DOR) applied only to patients whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1. The start date was defined as the date of the first documented confirmed CR or PR, and the end date corresponded to the date of the first documented confirmed progression or death from any cause. Patients who remained without progression or death from any cause were censored at the date of their last adequate tumor assessment prior to the initiation of any new antineoplastic therapy.

From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Throughout study completion, an average 5 years

The distribution of adverse events will be conducted through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study will be defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose, or events that are present prior to the first dose and increase in severity based on preferred term within 30 days following the last dose.

Throughout study completion, an average 5 years
Number of Participants With Trametinib Associated Serous Retinopathy Ocular Events
Zeitfenster: Up to approximately 3 years

Analysis of the optical coherence tomography data was performed to assess the incidence, type, and severity of trametinib-associated serous retinopathy ocular events, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grading system: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death related to adverse event).

Up to approximately 3 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. November 2021

Primärer Abschluss (Tatsächlich)

22. Januar 2025

Studienabschluss (Geschätzt)

25. Mai 2027

Studienanmeldedaten

Zuerst eingereicht

22. Juni 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Juni 2021

Zuerst gepostet (Tatsächlich)

25. Juni 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

21. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CDRB436J12301

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .